Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2007-10-31

Clinical Trial Update: Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer [NA]

View source ↗

Summary

A completed clinical trial update for Iscar as a second-line treatment for advanced non-small cell lung cancer. The study identifier is NCT00283478.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Iscar

Snippet

Sponsor: Kentuckiana Cancer Institute | Conditions: Non-Small Cell Lung Cancer | NA | Status: COMPLETED